Many clinical trials have tested the ability of the Wee1 inhibitor AZD1775 to impair the growth of different types of cancer alone or in combination with other cytostatic agents (e.g., cisplatin, paclitaxel, 5-fluorouracil, and topotecan)8. This evidence concerns the gene WEE1 and cancer.